BeOne Medicines is significantly bolstering its presence in the United States with a substantial $300 million investment earmarked for the…
Read More
Fungal gene editing world-first points to promising cancer medicines
A groundbreaking development from the University of Pennsylvania (PA, USA) has introduced a sophisticated gene-editing platform, fPE7max, specifically optimized for…
Read More
Parabilis Medicines Aims for $475 Million Nasdaq IPO to Advance Lead Cancer Asset Zolucatetide
Parabilis Medicines, a promising biotechnology firm, is strategically positioning itself for a significant public market debut, announcing its intention to…
Read More
Parabilis Medicines Aims for $475 Million Nasdaq IPO to Fund Pivotal Desmoid Tumour Trial and Pipeline Expansion
Parabilis Medicines, a biopharmaceutical company forging innovative therapeutic pathways, is charting a course for public market debut with a proposed…
Read More
Eli Lilly and Ascidian Therapeutics Forge Strategic Alliance to Pioneer Novel Genetic Medicines for Kidney Diseases
Eli Lilly and Company, a global pharmaceutical leader, has significantly bolstered its commitment to the cutting-edge field of genetic medicines…
Read More
Revolution Medicines’ Daraxonrasib Achieves Landmark Survival Extension in Pancreatic Cancer, Heralding New Era of Targeted Therapy
The field is ecstatic about the prospect of a targeted therapy meaningfully extending overall survival in pancreatic cancer. The 2026…
Read More
Regeneron Pharmaceuticals and Parabilis Medicines Forge Landmark $2.32 Billion Collaboration to Pioneer a New Era of Intracellular Therapies
Regeneron Pharmaceuticals has announced a monumental research collaboration with Parabilis Medicines, a deal valued at an impressive $2.32 billion. This…
Read More
EU Strikes Landmark Deal on Critical Medicines Act to Fortify Pharmaceutical Sector and Ensure Patient Supply
The European Union (EU) has achieved a significant legislative milestone with the provisional agreement on the Critical Medicines Act (CMA),…
Read More
Everest Medicines Acquires Hasten Biopharmaceuticals for $250 Million to Bolster Asia Pacific Chronic Disease Portfolio and Commercial Reach
Everest Medicines, a leading biopharmaceutical company focused on developing and commercializing innovative medicines for chronic diseases, has announced a significant…
Read More
Canada Invests C$79 Million in Aspect Biosystems to Accelerate Development of Bioengineered Cellular Medicines for Endocrine and Metabolic Diseases
Vancouver, BC – Aspect Biosystems, a pioneering company in the field of bioengineered cellular medicines, has received a significant C$79…
Read MoreYOU MAY HAVE MISSED
